Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

A significant increase in vitamin D supplementation was observed across the study period (p < 0.001; Figure 5).

Source: 3.6.5. Use of Vitamin D. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The study was designed as a retrospective, longitudinal observational analysis to evaluate outcomes in patients with LN lupus nephritis during the COVID-19 pandemic.

Source: Methods.

Patients were evaluated for renal parameters, including serum creatinine and estimated glomerular filtration rate calculated using the CKD-EPI formula; inflammatory marker (C-reactive protein, CRP), and hematological parameters, including hemoglobin concentration, white blood cell count (WBC) with differentiation into neutrophils and lymphocytes, and platelet count.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Lupus Nephritis During the COVID-19 Pandemic: Challenges and Implications Before, During, and After

Observational study · Biomedicines · 2025

Original publication title

Lupus Nephritis During the COVID-19 Pandemic: Challenges and Implications Before, During, and After

Michał Komorniczak; Piotr Stępniewski; Barbara Bułło-Piontecka; Katarzyna Aleksandra Lisowska; Alicja Dębska-Ślizień; Anna Wardowska

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Patients with systemic lupus erythematosus (SLE), particularly those with lupus nephritis (LN), are at increased risk of severe COVID-19 outcomes due to immune dysregulation and immunosuppressive therapy. Renal transplant recipients with prior LN (LN-RTX) combine chronic immunosuppression with residual autoimmune risk. This study aimed to evaluate renal function trajectories and disease activity in LN patients during the COVID-19 pandemic, comparing transplant recipients with conservatively managed patients (LN-CT), and to assess the potential effects of COVID-19 vaccination.

Methods:

A retrospective cohort of 111 biopsy-confirmed LN patients followed between 2019 and 2023 was analyzed at four time points: pre-pandemic (T0), first pandemic year (T1), second pandemic year (T2), and post-pandemic (T3). Changes in renal function, disease activity markers, and treatment patterns were compared between LN-CT (n = 100) and LN-RTX (n = 11) groups, with additional analysis by vaccination status.

Results:

Renal function declined significantly in LN-CT (median eGFR: from 76.5 to 66.5 mL/min/1.73 m2; p < 0.001) but remained stable in LN-RTX patients despite higher comorbidity rates. LN activity (proteinuria, erythrocyturia) and glucocorticoid/MMF use decreased over time. Vaccinated patients showed a statistically significant decline in eGFR (p = 0.00046), though causality remains uncertain.

Conclusions:

Renal outcomes during the pandemic differed by treatment modality, with LN-RTX patients maintaining stable function despite higher risk. Adjusted immunosuppression and vigilant monitoring may have supported these outcomes. Further prospective studies should clarify vaccine-related renal effects in LN populations.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Patients with systemic lupus erythematosus (SLE), particularly those with lupus nephritis (LN), are at increased risk of severe COVID-19 outcomes due to immune dysregulation and immunosuppressive therapy. Renal transplant recipients with prior LN (LN-RTX) combine chronic immunosuppression with residual autoimmune risk. This study aimed to evaluate renal function trajectories and disease activity in LN patients during the COVID-19 pandemic, comparing transplant recipients with conservatively managed patients (LN-CT), and to assess the potential effects of COVID-19 vaccination.

Source: Background:

Abstract: Results

Renal function declined significantly in LN-CT (median eGFR: from 76.5 to 66.5 mL/min/1.73 m2; p < 0.001) but remained stable in LN-RTX patients despite higher comorbidity rates. LN activity (proteinuria, erythrocyturia) and glucocorticoid/MMF use decreased over time. Vaccinated patients showed a statistically significant decline in eGFR (p = 0.00046), though causality remains uncertain.

Source: Results:

Abstract: Conclusions

Renal outcomes during the pandemic differed by treatment modality, with LN-RTX patients maintaining stable function despite higher risk. Adjusted immunosuppression and vigilant monitoring may have supported these outcomes. Further prospective studies should clarify vaccine-related renal effects in LN populations.

Source: Conclusions:
Authors’ abstract

Background:

Patients with systemic lupus erythematosus (SLE), particularly those with lupus nephritis (LN), are at increased risk of severe COVID-19 outcomes due to immune dysregulation and immunosuppressive therapy. Renal transplant recipients with prior LN (LN-RTX) combine chronic immunosuppression with residual autoimmune risk. This study aimed to evaluate renal function trajectories and disease activity in LN patients during the COVID-19 pandemic, comparing transplant recipients with conservatively managed patients (LN-CT), and to assess the potential effects of COVID-19 vaccination.

Methods:

A retrospective cohort of 111 biopsy-confirmed LN patients followed between 2019 and 2023 was analyzed at four time points: pre-pandemic (T0), first pandemic year (T1), second pandemic year (T2), and post-pandemic (T3). Changes in renal function, disease activity markers, and treatment patterns were compared between LN-CT (n = 100) and LN-RTX (n = 11) groups, with additional analysis by vaccination status.

Results:

Renal function declined significantly in LN-CT (median eGFR: from 76.5 to 66.5 mL/min/1.73 m2; p < 0.001) but remained stable in LN-RTX patients despite higher comorbidity rates. LN activity (proteinuria, erythrocyturia) and glucocorticoid/MMF use decreased over time. Vaccinated patients showed a statistically significant decline in eGFR (p = 0.00046), though causality remains uncertain.

Conclusions:

Renal outcomes during the pandemic differed by treatment modality, with LN-RTX patients maintaining stable function despite higher risk. Adjusted immunosuppression and vigilant monitoring may have supported these outcomes. Further prospective studies should clarify vaccine-related renal effects in LN populations.

Publication and source details

Original title: Lupus Nephritis During the COVID-19 Pandemic: Challenges and Implications Before, During, and After

Michał Komorniczak; Piotr Stępniewski; Barbara Bułło-Piontecka; Katarzyna Aleksandra Lisowska; Alicja Dębska-Ślizień; Anna Wardowska

Biomedicines · 2025

* Correspondence: mkomorniczak@gumed.edu.pl (M.K.); anna.wardowska@gumed.edu.pl (A.W.)
†

These authors contributed equally to this work.

© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Medical University of Gdańsk, educational934 01-10024Polpharma Scientific Foundation1/XX/2021This research was funded by the Medical University of Gdańsk, educational grant no. 934 01-10024 (project 000599), and by the Polpharma Scientific Foundation, grant no. 1/XX/2021, for the project “The immune system of patients with lupus nephritis post SARS-CoV-2 infection” (principal investigator: A.W.). The Medical University of Gdańsk funded the APC.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:20:45.093236+00:00

DOI: 10.3390/biomedicines13122984 · PMC12731086